FDA Watch: Agency Clears Record Number of New Medical Devices in 2020

Spurred by the pandemic, the FDA authorized more novel medical devices in 2020 than it ever has in any single year. I know what you’re thinking. “Of course, new medical device approvals were off the chart because it was a pandemic year.” True, there was a significant volume of emergency use authorizations for devices to diagnose and treat COVID-19; but the flow of clearances for non-COVID-19-related devices was also unprecedented.

The Emergency Use Authorization Factor

Despite a slight dip in 2019, new medical device approvals have been steadily trending upward over the past decade. Even so, what occurred in 2020 represents an aberration from previous patterns, as total FDA new medical device approvals completely crushed the previous high of 2017.

Clearly, one major reason for the spike is that the 2020 totals include not just full-blown clearance but also EUAs, which represent a less rigorous pathway to approval that the FDA uses in response to public health emergencies. Although this was hardly the first time that the opening of the EUA pipeline benefited medical device makers, the COVID-19 crisis was—and remains—bigger and more urgent than any previous public health emergency to arise under the FDA’s modern regulatory regime, paving the way for novel ventilators, laboratory tests, sample collection devices, personal protective equipment and other products to diagnose and treat the virus.

The Year in Device Approvals

A new article in the New England Journal of Medicine written by Jeff Shuren and William Maisel, respectively, the directors of the FDA’s Center for Devices and Radiological Health (CDRH), and the CDRH Office of Product Evaluation and Quality documents what happened. The CDRH was stretched unusually thin during the year, the authors explain, due to a deluge of submissions coming, including both COVID-19 products coming through the EUA pathway. Shuren and Maisel said the agency issued 625 EUAs for medical devices in 2020, including several designated as novel medical devices such as in vitro diagnostics for COVID-19.

Surprisingly, though, the deluge extended beyond coronavirus. The flow of submissions for non-COVID-19 products also exceeded previous years, with device makers seeking clearance via the 510(k), Breakthrough Device and De Novo pre-market approval channels, as well as the humanitarian device exemption. Non-COVID-19 novel medical devices products that the FDA cleared for the first time in 2020 included:

• The first liquid biopsy next generation-sequencing companion diagnostic test;
• The first cardiac ultrasound software using artificial intelligence to aid in capturing quality diagnostic images;
• An automated insulin delivery and monitoring system for young patients;
• An anterior cruciate ligament implant; and
• A game-based digital therapeutic to help children with attention deficit hyperactivity disorder.

**************

This article originally appeared in G2 Intelligence, Laboratory Industry Report, March 2021.